Clinicians more likely to prescribe benzodiazepine if they don’t believe in potential risks

Patients of clinicians who believe the potential harms of benzodiazepines are low were at a greater risk of being prescribed them, survey results of primary care physicians showed in Annals of Family Medicine.
Benzodiazepines are a leading contributor to prescription drug deaths, yet the proportion of adults prescribed benzodiazepines has remained unchanged, Donovan T. Maust, MD, associate director of the geriatric psychiatry program at the University of Michigan, and colleagues wrote.
Maust and colleagues sought to identify whether clinician beliefs influence benzodiazepine prescribing. The

Roflumilast cream significantly reduces itch in chronic plaque psoriasis

Arcutis Biotherapeutics announced positive results from two pivotal phase 3 studies evaluating Zoryve cream as a once daily, topic treatment for chronic plaque psoriasis, according to a company press release.
The results evaluating Zoryve (roflumilast cream 0.3%), a nonsteroid, phosphodiesterase-4 inhibitor, were published in The Journal of the American Medical Association.
“Itch is the symptom that psoriasis patients identify as the main driver of their disease severity, so it is important for any psoriasis therapy to control this symptom,” Patrick Burnett MD, PhD, FAAD, Chief

FDA grants fast track, RMAT designations to CAR-T for advanced non-Hodgkin lymphoma

The FDA granted fast track and regenerative medicine advanced therapy designations to CB-010, a chimeric antigen receptor T-cell therapy, for the treatment of relapsed or refractory B-cell non-Hodgkin lymphoma.
The fast track designation applies to patients with relapsed or refractory B-cell non-Hodgkin lymphoma. The regenerative medicine advanced therapy (RMAT) designation applies to patients with relapsed or refractory large B-cell lymphoma.
CB-010 (Caribou Biosciences) is an allogeneic, CD19-directed CAR T-cell therapy.
The investigational agent is genetically engineered using CRISPR/Cas9

Comprehensive Care for Joint Replacement model penalized safety-net hospitals

Results showed safety-net hospitals and hospitals with greater populations of Black and Hispanic patients have struggled to meet the lower spending benchmarks implemented by Medicare and the Comprehensive Care for Joint Replacement model.
“Medicare lowered spending targets for high-risk hospitals by shifting from hospital-specific targets to multi-hospital shared targets that did not account for differences in medical or social case mix between hospitals,” the researchers wrote in the study.
To analyze the trends in penalization status and equity implications under the Comprehensive

Fatty liver disease conditions ‘change the healthy heart to a failing heart’

CVD risk increases with the severity of nonalcoholic fatty liver disease, and both CV and liver events are “highly related” to the degree of hepatic fibrosis present, according to a speaker.
CVD remains the leading cause of death in adults with nonalcoholic steatohepatitis (NASH) and liver fibrosis, Bart Staels, PhD, professor at the Faculty of Pharmacy, University of Lille, France, said during a presentation at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease. Data also show adults with biopsy-proven NAFLD have increased incidence of major adverse

New position statement explicitly supports family, career ambitions

The Society of NeuroInterventional Surgery (SNIS), a scientific and educational association with more than 1,000 members dedicated to advancing the specialty of neurointerventional surgery, has made a statement in support of pregnancy and parental leave policies for those in the field who are birthing or non-birthing parents including those who adopt, foster, and the like.

New research explores options for motherhood in lung cancer patients

New research from the University of Colorado (CU) Cancer Center highlights the need for additional data collection for women hoping to have successful pregnancies while undergoing treatment for lung cancer. Specifically, they focus on the diagnosis of advanced oncogene-driven non-small cell lung cancer (NSCLC) that disproportionately affects women of reproductive age.